

FORM PTO-1449 (Rev. 2-32) SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	U.S. Department of Commerce Patent and Trademark Office		Atty. Docket No. 07-1009-WO-US	Serial No. 10/580,164
	Applicant: Mark Ian Christie			
	Filing Date: May 18, 2006	Group: 1646		

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
/P.M./	6,274,711	08/14/01	Golstein, et al			

FOREIGN PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Country	Class	Subclass	Translation Yes No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).

		Kotake, <i>et al.</i> , <i>IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis</i> , The Journal of Clinical Investigation, 103:1345-1352 (1999).
		Chabaud, <i>et al.</i> , <i>Contribution of Interleukin 17 to Synovium Matrix Destruction in Rheumatoid Arthritis</i> , Cytokine, 12:1092-1099 (2000).
EXAMINER		DATE CONSIDERED
/Prema Mertz/		06/17/2008

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.